Ritedose Awarded 503B Compounded Medications Agreement with Premier, Inc.

Hitesh
Medications

Premier Inc., a renowned healthcare improvement firm running one of the biggest group purchasing organisations in the country, has awarded a group purchasing deal to Ritedose, a 503B outsourcing plant in South Carolina (GPOs). With effect from January 1, 2023, the new arrangement enables Premier members to choose whether to benefit from exclusive price and conditions that Premier has pre-negotiated for Ritedose’s whole line of compounded drugs.

Hospitals, healthcare systems, surgery centres, and other healthcare organizations can purchase ready-to-use, single dose syringe supplies from Ritedose through their 503B outsourcing service.

“We’re pleased to work with Premier and its extensive healthcare network to provide quality medication at affordable prices”, “Decades of successful cGMP production, extensive development resources and significant manufacturing capacity mean we have a ready supply of medication always available, to help Premier’s members avoid disruptions in patient care. We’re excited to continue meeting the outsourcing needs of healthcare organizations across the country.”

Jody Chastain, President and CEO, Ritedose

Premier, Inc. is a market-leading provider of healthcare improvement services, bringing together an alliance of over 4,400 hospitals and health systems in the United States as well as around 250,000 more providers and organizations to transform healthcare. Premier delivers better treatment and outcomes at a lesser cost with integrated data and analytics, collaboratives, supply chain solutions, consultancy, and other services.

Next Post

Newly Developed RSV Vaccine Offers Immunity While Lowering the Risk of Dangerous Pulmonary Inflammation

Researchers at Artificial Cell Technologies (ACT) have created a wholly synthetic RSV microparticle vaccine that, when administered to mice, produced a protective immune response while also reducing pulmonary inflammation. In the journal Vaccines, further findings from their preclinical research have been revealed. The possibility for severe pulmonary inflammation defined by […]
Vaccine